Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (TREAT-HF)

  • End date
    Jun 30, 2024
  • participants needed
  • sponsor
    Virginia Commonwealth University
Updated on 23 May 2022
heart failure
cardiac mri


To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.


The current study will test the hypothesis that among adult age survivors of cancer diagnosed at age < 39 years treatment of Stage B heart failure with sacubitril-valsartan is feasible and safe.

Condition Heart Failure, Heart Dysfunction
Treatment Valsartan, Sacubitril-Valsartan
Clinical Study IdentifierNCT05194111
SponsorVirginia Commonwealth University
Last Modified on23 May 2022


Yes No Not Sure

Inclusion Criteria

Age </= 39 years old at time of cancer diagnosis
Clinical records adequate to determine diagnosis and treatment regimen
Previous anthracycline chemotherapy
Global longitudinal strain <18% and/or
L VEF below the institutional lower limit of normal but >/=40% on echocardiogram or cardiac MRI
No symptoms of heart failure (shortness of breath, fatigue, swelling). Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath)

Exclusion Criteria

Age <18 years
Inability to obtain consent from patient or legally authorized representative
Active acute or chronic psychiatric illness that in the opinion of the investigator may prevent compliance with study instructions
Limited English or Spanish proficiency that in the opinion of the investigator may prevent understanding the content of the informed consent form or safely completing the study procedures
Participation in another concurrent intervention study within 30 days or treatment with an investigational drug within 5 half-lives prior to randomization
Greater than mild mitral or aortic valve regurgitation/stenosis known pre-cancer therapy
Severe kidney disease (GFR <30 mL/min/1.73m2)
Chronic hyperkalemia (>5mmol/L)
Evidence of COVID-19 within the last 60 days or recent (21 days) exposure to close personal contact with COVID-19
Greater than moderate tricuspid or pulmonary valve regurgitation/stenosis known pre-cancer therapy
Hemodynamically significant congenital heart disease in the opinion of the investigator (not including PFO/small ASD or small VSD)
Greater than moderate pericardial effusion
Constrictive cardiomyopathy diagnosed pre-cancer therapy
Family history of genetic cardiomyopathy
Evidence of infiltrative cardiomyopathy
Symptomatic heart disease based on NYHA classification
Allergy to valsartan or sacubitril
Inability to complete CMR or 6-minute walk test
Inability to measure non-invasive blood pressure and heart rate in the ambulatory/home setting
History of severe hypersensitivity reactions to gadolinium-based contrast agents (will perform limited cardiac imaging without contrast)
Concomitant use of other ACE inhibitors or ARBs, aliskiren, NSAIDs or lithium or the inability to stop these medications for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note